| Increlex (mecasermin) / Eton Pharma |
2012-001239-30: THE EFFECTS OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 ON THE NUTRITIONAL STATUS IN PATIENTS WITH LIVER CIRRHOSIS: A PILOT-STUDY. DE EFFECTEN VAN RECOMBINANTE HUMANE IGF-I OP DE VOEDINGSTOESTAND VAN LEVERCIRROSE PATIENTEN: EEN PILOT STUDIE. |
|
|
| Ongoing | 4 | 6 | Europe | Solution for injection, INCRELEX | Foundation for Liver Research, Foundation for Liver Research | Liver cirrhosis Levercirrose, Replacement of normal liver tissue by fibrosis, scar tissue leading to the loss of liver function. Vervanging van normale lever weefsel door fibrose, litteken weefsel waardoor de lever zijn functie verliest., Diseases [C] - Digestive System Diseases [C06] | | | | |
2010-019737-94: ESTUDIO ABIERTO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TRÓFICO IGF-I EN LA ATAXIA CEREBELOSA DEGENERATIVA |
|
|
| Ongoing | 4 | 20 | Europe | -, INCRELEX 10 mg/ml solución inyectable., INCRELEX 10 mg/ml solución inyectable. | FIBHULP | Ataxia cerebelosa degenerativa de grado leve a moderado | | | | |
2011-004104-38: ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TRÓFICO IGF-I EN LA ATAXIA DE FRIEDREICH |
|
|
| Ongoing | 3 | 30 | Europe | INCRELEX 10 mg/ml solución inyectable, INCRELEX 10 mg/ml solución inyectable | FIBHULP, Ministerio de Sanidad, Política Social e Igualdad | Pacientes con ataxia de Friedreich | | | | |
2010-022215-19: Combined growth hormone and IGF1 therapy in paediatric Crohn'd disease |
|
|
| Ongoing | 2 | 24 | Europe | Increlex 10mg/ml solution for injection, NutropinAq 10mg/2ml solution for injection, Solution for injection, Increlex, NutropinAq® | Greater Glasgow & Clyde NHS | Impaired growth in Paediatric Crohn's disease, Impaired growth in Paediatric Crohn's disease, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT01970345: A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder |
|
|
| Terminated | 2 | 3 | US | IGF-1, Increlex, mecasermin, Placebo/saline, Saline | Icahn School of Medicine at Mount Sinai, Autism Science Foundation | Autism Spectrum Disorder | 09/17 | 09/17 | | |
NCT02636270: IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency |
|
|
| Completed | 1/2 | 7 | NA | Increlex, rhIGF-1 | Children's Hospital Medical Center, Cincinnati | Short Stature | 10/22 | 12/22 | | |
EuIGFD, NCT00903110: Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD). |
|
|
| Recruiting | N/A | 500 | Europe, US, RoW | Increlex® | Ipsen | IGF1 Deficiency | 12/27 | 12/27 | | |
|
